cryptosporidium
aspergillu
speci
b
lymphocyt
defect
result
infect
bacteria
streptococcu
pneumonia
haemophilu
influenza
staphylococcu
aureu
well
echo
viru
protozoa
giardia
wherea
phagocyt
defect
result
infect
staphylococcu
pseudomona
aspergillu
speci
consid
infect
undergo
hsct
also
import
note
recogn
sequenc
risk
differ
infect
differ
time
hsct
equat
differ
aspect
immun
system
compromis
time
fig
within
first
day
patient
neutropen
signific
risk
infect
gramneg
gramposit
bacteria
along
herpessimplex
viru
day
transplant
tcell
immun
still
limit
rise
number
fungal
cmv
infect
later
infect
commonli
caus
varicella
zoster
viru
vzv
pneumonia
whatev
caus
immunocompromis
possibl
infect
requir
differ
approach
investig
manag
immunocompet
child
although
understand
type
immunocompromis
help
predict
like
organ
infect
immunocompromis
also
need
consid
system
affect
infect
occur
system
bodi
respiratori
system
gastrointestin
tract
especi
vulner
larg
surfac
area
barrier
defenc
necess
compromis
need
transport
oxygen
nutrient
respect
dissemin
viral
fungal
infect
anoth
import
risk
whilst
central
venou
cathet
cvc
infect
also
constitut
frequent
problem
immunocompromis
discuss
turn
respiratori
tract
expos
wide
varieti
differ
organ
pneumocysti
jiroveci
pneumonia
pcp
cmv
aspergillu
particularli
import
well
recogn
sourc
infect
immunocompromis
host
howev
signific
pathogen
recent
identifi
includ
respiratori
syncyti
viru
rsv
influenza
parainfluenza
adenoviru
picornavirus
measl
human
metapneumoviru
cocaviru
coronavirus
polyomavirus
wu
pneumon
bronchiol
common
present
respiratori
infect
lobar
pneumonia
may
also
occur
defect
immuneinflammatori
respons
mean
patient
may
respiratori
symptom
low
threshold
investig
one
studi
bronchoalveolar
lavag
bal
perform
children
immunodefici
prehsct
pathogen
isol
six
asymptomat
pcp
bacteria
commonli
identifi
organ
follow
parainfluenza
viru
cmv
rsv
influenza
b
human
herp
slatter
et
al
accur
diagnosi
depend
collect
right
sampl
use
appropri
diagnost
techniqu
includ
throat
swab
nasopharyng
aspir
npa
bal
fluid
even
lung
biopsi
deem
appropri
sampl
must
sent
look
specif
bacteria
fungi
virus
respiratori
pathogen
isol
upper
respiratori
tract
exampl
pcp
identifi
npa
whilst
organ
found
npa
may
found
lower
respiratori
tract
highlight
import
bal
diagnost
procedur
lung
biopsi
may
particularli
import
diagnosi
fungal
infect
especi
neg
bal
patient
persist
sign
symptom
chest
xray
chang
diagnosi
may
requir
cultur
organ
bacteria
mycobacteria
virus
immunofluoresc
virus
polymeras
chain
reaction
bacteria
virus
fungi
antigen
test
eg
galactomannan
aspergillu
serolog
test
often
ineffect
immunodefici
children
may
mount
antibodi
respons
may
receiv
intraven
immunoglobulin
ivig
make
result
imposs
interpret
import
know
test
avail
local
laboratori
discuss
local
microbiologist
virologist
essenti
ensur
right
sampl
sent
appropri
investig
miss
seriou
infect
high
resolut
computer
tomographi
hrct
chest
sensit
chest
xray
aim
classifi
diseas
interstiti
airway
involv
airspac
may
aid
diagnosi
pcp
histor
associ
hiv
also
signific
caus
morbid
group
immunocompromis
patient
particularli
haematolog
malign
brain
tumour
requir
prolong
cours
steroid
prolong
neutropaenia
lymphopaenia
undergo
hsct
therefor
pcp
prophylaxi
import
recommend
recent
cochran
review
green
et
al
treatment
gener
form
cotrimoxazol
given
three
time
per
week
children
toler
cotrimoxazol
either
dapson
aerosol
pentamidin
use
p
jiroveci
infect
commonli
present
tachypnoea
nonproduct
cough
fever
sever
vari
usual
subacut
diffus
pneumon
chest
xray
chang
subtl
often
take
form
bilater
diffus
interstiti
chang
although
lobar
miliari
nodular
chang
seen
hrct
may
show
ground
glass
attenu
consolid
nodul
thicken
interlobular
septa
thin
wall
cyst
mortal
rang
treat
reach
nearli
left
untreat
identif
pcp
difficult
definit
diagnosi
depend
identifi
organ
respiratori
tract
secret
lung
tissu
usual
tracheal
secret
bronchial
secret
lung
biopsi
recent
pcr
technolog
develop
identifi
pcp
secret
review
children
diagnos
sever
combin
immun
defici
scid
treat
supraregion
center
identifi
pcp
one
diagnos
bal
prior
transfer
supraregion
center
one
diagnos
nasopharyng
secret
bal
seven
diagnos
bal
alon
one
diagnosi
made
lung
biopsi
perform
berrington
et
al
recommend
first
line
pcp
treatment
high
dose
cotrimoxazol
howev
caus
number
advers
effect
exampl
neutropenia
anaemia
renal
dysfunct
rash
vomit
diarrhea
toler
cotrimoxazol
improv
day
treatment
chang
differ
agent
choic
includ
pentamidin
atovaquon
clindamycinprimaquin
dapson
experi
agent
children
limit
corticosteroid
given
adjunct
therapi
moder
sever
pcp
number
studi
shown
reduct
acut
respiratori
failur
decreas
need
ventil
decreas
mortal
sleasman
et
al
bye
et
al
mclaughlin
et
al
recent
cochran
review
support
use
corticosteroid
hivinfect
patient
pcp
especi
substanti
hypoxaemia
briel
et
al
wide
varieti
respiratori
virus
also
caus
signific
morbid
mortal
immunocompromis
measl
import
respiratori
pathogen
immunocompromis
host
must
rememb
typic
rash
may
develop
mortal
high
especi
amongst
patient
leukaemia
undergo
hsct
prospect
multicent
review
patient
undergo
hsct
found
direct
rsvassoci
mortal
mortal
directli
attribut
influenza
ljungman
et
al
respiratori
virus
often
present
nonspecif
symptom
progress
signific
lower
respiratori
tract
infect
chest
xray
often
show
pneumon
pictur
diffus
interstiti
chang
hrct
may
show
peribronchi
thicken
ground
glass
attenu
without
consolid
lobular
distribut
diagnosi
requir
identif
organ
respiratori
secret
may
possibl
nasopharyng
secret
throat
swab
may
requir
invas
test
bronchoscopi
bal
laboratori
techniqu
includ
immunofluoresc
pcr
viral
cultur
treatment
mainli
support
specif
treatment
option
evolv
make
rapid
accur
diagnosi
increasingli
import
appropri
isol
infectioncontrol
measur
essenti
prevent
transmiss
immunocompromis
patient
virus
easili
spread
one
uk
studi
hsct
unit
identifi
case
rsv
one
winter
season
eight
nine
rsv
strain
could
test
molecular
method
found
ident
taylor
et
al
specif
treatment
rsv
infect
includ
ribavirin
rsv
monoclon
antibodi
palivizumab
ribavirin
given
oral
intraven
via
inhal
howev
aerosol
rout
use
frequent
rsv
infect
histor
pool
hyperimmun
rsv
immunoglobulin
propos
addit
treatment
supersed
antirsv
monoclon
antibodi
palivizumab
combin
inhal
ribavirin
intraven
palivizumab
shown
encourag
result
palivizumab
shown
safe
well
toler
patient
undergo
hsct
suggest
better
outcom
improv
surviv
compar
ribavirin
alon
boeckh
et
al
chavezbueno
et
al
two
group
drug
avail
treatment
influenza
name
adamantan
effect
influenza
eg
rimantadin
neuraminidas
inhibitor
effect
influenza
b
eg
oseltamivir
recent
year
develop
increas
resist
adamantan
neuraminidas
inhibitor
shown
reduc
durat
ill
one
day
given
immunocompet
host
within
h
onset
symptom
although
data
benefit
treat
influenza
immunocompromis
patient
neuraminidas
inhibitor
use
appear
sensibl
safe
thu
far
specif
treatment
avail
rhinoviru
coronaviru
human
metapneumoviru
ribavirin
propos
treatment
parainfluenza
viru
infect
evid
far
benefit
disappoint
although
littl
clinic
data
use
ribavirin
measl
pneumon
vitro
activ
therefor
due
high
level
mortal
condit
consid
review
respiratori
viral
infect
children
primari
immun
defici
hsct
unit
found
patient
admit
hsct
respiratori
viral
infect
paramyxovirus
rsv
parainfluenza
iiv
treat
aerosol
ribavirin
ivig
five
patient
also
receiv
nebul
immunoglobulin
corticosteroid
three
five
surviv
compar
two
six
receiv
nebul
treatment
conclud
nebul
treatment
well
toler
could
use
adjunct
therapi
crook
et
al
children
undergon
hsct
infect
inflamm
becom
inextric
interwoven
gener
pneumon
case
addit
need
antiinfect
agent
immunomodul
requir
agent
steroid
ivig
antitumour
necrosi
factor
monoclon
antibodi
gastrointestin
tract
also
expos
wide
varieti
organ
virus
particular
concern
immunocompromis
child
notabl
enterovirus
adenoviru
rotaviru
calicivirus
also
protozoa
mainli
cryptosporidium
giardia
present
commonli
diarrhea
vomit
may
protract
cryptosporidium
also
respons
ascend
cholang
liver
diseas
case
identif
caus
organ
difficult
cultur
may
requir
identifi
virus
pcr
use
exampl
adenoviru
sensit
microscopi
alon
detect
cryptosporidium
prevent
transmiss
immunocompromis
patient
essenti
must
strict
adher
infectioncontrol
polici
prevent
hospit
ward
becom
sourc
infect
one
studi
look
extent
gastroenter
viru
contamin
pediatricprimari
immunodefici
ward
gener
pediatr
ward
found
virus
environment
swab
respect
interestingli
contamin
object
use
parent
rather
stafffor
exampl
parent
room
televis
parent
toilet
tap
microwav
use
parent
pediatricprimari
immunodefici
ward
gallimor
et
al
highlight
import
ensur
parent
visitor
well
staff
compli
hand
wash
infect
control
measur
rotaviru
infect
usual
rel
mild
selflimit
immunocompet
lead
persist
vomit
diarrhea
untreat
sever
malnutrit
immunocompromis
identifi
stool
use
enzym
immunoassay
may
also
identifi
electron
microscopi
specif
treatment
fluid
electrolyt
manag
import
oral
administ
immunoglobulin
use
case
calicivirus
name
norovirus
sapovirus
also
caus
signific
problem
immunocompromis
symptomat
infect
viru
shed
prolong
exampl
one
case
report
child
undergo
hsct
cartilag
hair
hypoplasia
demonstr
noroviru
shed
day
follow
transplant
period
immun
reconstitut
child
symptomat
throughout
time
gallimor
et
al
specif
treatment
meticul
manag
fluid
electrolyt
nutrit
support
essenti
allow
time
immun
reconstitut
consequ
viral
clearanc
adenoviru
discuss
detail
section
dissemin
infect
immunocompromis
cryptosporidium
speci
oocystform
protozoa
caus
wateri
diarrhea
result
sever
dehydr
even
death
treat
diseas
normal
confin
gastrointestin
tract
risk
biliari
tree
pulmonari
even
dissemin
diseas
immunocompromis
infect
may
diagnos
identif
oocyst
microscopi
enzym
immunoassay
also
use
pcr
help
treatment
cryptosporidium
infect
difficult
number
agent
propos
includ
nitazoxanid
paromomycin
rifabutin
macrolid
evid
limit
recent
review
indic
nitazoxanid
may
reduc
parasit
load
therefor
use
abubakar
et
al
author
experi
azithromycin
nitazoxanid
safer
option
posthsct
patient
paromomycin
associ
signific
hear
loss
particularli
given
ciclosporin
support
care
remain
essenti
hiv
antiretrovir
therapi
associ
improv
count
result
improv
cryptosporidium
infect
giardia
intestinali
flagel
protozoan
exist
trophozoit
cyst
form
cyst
infect
form
children
humor
immunodefici
particularli
risk
chronic
symptomat
infect
foulsmel
stool
abdomin
distens
anorexia
cyst
may
identifi
stool
microscopi
use
immunofluoresc
antibodi
test
treatment
metronidazol
tinidazol
nitazoxanid
may
necessari
use
combin
therapi
immunocompromis
fail
respond
singleag
treatment
dissemin
viral
infect
immunocompromis
particular
concern
signific
culprit
adenoviru
member
human
herp
viru
cmv
ebv
hsv
vzv
affect
lung
gastrointestin
tract
brain
result
varieti
symptom
reactiv
latent
herp
viral
infect
common
primari
infect
sot
hsct
investig
use
pcr
techniqu
allow
earli
diagnosi
quantif
viral
load
possibl
adenoviru
cmv
ebv
prophylaxi
prevent
cmv
hsv
reactiv
use
children
undergo
hsct
mani
sot
surveil
highrisk
patient
enabl
preemptiv
treatment
given
damag
diseas
occur
treatment
depend
caus
viru
adenoviru
usual
respons
rel
minor
upper
respiratori
tract
gastrointestin
infect
result
lifethreaten
pneumonia
mening
enceph
dissemin
diseas
immunocompromis
risk
patient
receiv
allogen
bone
marrow
transplant
activ
graft
versu
host
diseas
receiv
total
bodi
irradi
number
differ
speci
adenoviru
divid
serotyp
primarili
associ
respiratori
tract
other
predilect
gastrointestin
tract
young
children
particularli
vulner
often
carri
adenoviru
gastrointestin
tract
predispos
reactiv
dissemin
becom
immunocompromis
view
screen
import
immunocompromis
adenoviru
usual
identifi
urin
stool
sometim
respiratori
secret
prior
identifi
blood
studi
patient
undergo
hsct
screen
adenoviru
stool
urin
throat
swab
peripher
blood
post
transplant
period
posit
adenovir
pcr
least
one
screen
test
associ
clinic
sign
unless
detect
peripher
blood
even
median
delay
week
first
detect
adenoviru
patient
demonstr
clinic
sign
one
studi
mortal
high
adenoviru
detect
peripher
blood
highlight
import
earli
recognit
consider
preemptiv
use
antivir
lion
et
al
success
treatment
adenoviru
infect
far
limit
wide
use
agent
cidofovir
ribavirin
may
given
togeth
ivig
although
cidofovir
potent
nephrotox
effect
greatli
reduc
concurr
use
intraven
hyperhydr
probenecid
cidofovir
shown
effect
adenoviru
consid
best
firstlin
treatment
data
clinic
effect
ribavirin
adenovir
infect
conflict
vitro
data
suggest
ribavirin
alon
activ
subgenu
c
serotyp
posthsct
patient
adenovir
infect
immun
suppress
reduc
much
possibl
tcell
immun
reconstitut
import
viral
elimin
cmv
infect
often
asymptomat
immunocompet
howev
immunocompromis
lead
pneumonia
coliti
retin
cmv
persist
latent
form
primari
infect
result
reactiv
someon
later
becom
immunosuppress
exampl
undergo
hsct
cmv
identifi
respiratori
secret
urin
blood
adenoviru
pcr
screen
may
use
identifi
viru
child
becom
symptomat
especi
case
reactiv
like
immunosuppress
treatment
usual
intraven
ganciclovir
foscarnet
cidofovir
secondlin
treatment
oral
valganciclovir
well
absorb
also
option
treatment
foscarnet
also
use
case
children
undergo
hsct
avoid
myelosuppress
effect
ganciclovir
ivig
use
alongsid
antivir
therapi
one
case
report
ganciclovirand
foscarnetresist
cmv
success
treat
artesun
shapira
et
al
also
interest
new
antivir
agent
maribavir
resist
cmv
ebv
associ
lymphoprolif
disord
immunocompromis
replic
ebv
b
cell
usual
inhibit
natur
killer
cell
antibodydepend
cell
cytotox
tcell
cytotox
respons
therefor
children
cellular
immun
defici
risk
uncontrol
lymphoprolifer
particular
risk
children
transplant
recipi
sot
hsct
hiv
ebv
detect
blood
pcr
viral
load
monitor
alongsid
monitor
viru
import
monitor
sign
lymphoprolifer
clinic
biochem
biopsi
suspici
lesion
often
need
make
diagnosi
ebv
infect
requir
treatment
caus
b
lymphoprolifer
posttranspl
lymphoprolif
diseas
ptld
may
take
form
monoclon
antibodi
rituximab
chemotherapi
radiotherapi
decreas
immunosuppress
whenev
possibl
posttranspl
patient
import
recent
encourag
result
work
cytotox
tcell
therapi
ptld
involv
infus
ebvspecif
cytotox
lymphocyt
ctl
gener
ebv
seroposit
blood
donor
one
recent
multicent
studi
patient
fail
convent
therapi
recruit
monitor
respons
patient
achiev
complet
remiss
three
show
partial
respons
haqu
et
al
primari
infect
immunocompet
host
lead
typic
clinic
pictur
roseola
nonspecif
febril
ill
viru
remain
latent
primari
infect
therefor
similar
cmv
reactiv
immunocompromis
state
import
pathogen
immunocompromis
probabl
underestim
mani
lab
screen
infect
thu
mani
infect
may
recogn
caus
fever
rash
hepat
pneumonia
enceph
well
bone
marrow
suppress
also
appear
synergist
effect
interact
infecti
agent
cmv
adenoviru
fungi
identifi
quantifi
blood
sampl
pcr
treatment
necessari
intraven
ganciclovir
foscarnet
primari
varicella
infect
result
chickenpox
common
gener
selflimit
childhood
ill
immunocompromis
signific
risk
primari
reactiv
diseas
becom
dissemin
particularli
associ
lymphocyt
defect
vzv
second
common
caus
viral
pneumon
children
aid
rememb
fatal
vzv
infect
report
case
immunosuppress
medic
corticosteroid
dose
mgkgday
prednisolon
week
viru
identifi
vesicular
fluid
treatment
usual
form
intraven
aciclovir
oral
valaciclovir
use
altern
older
children
import
area
consid
relat
vzv
infect
postexposur
prophylaxi
although
longterm
prophylaxi
vzv
usual
recommend
postexposur
prophylaxi
nonimmun
immunocompromis
children
import
two
option
avail
wide
use
varicella
zoster
immunoglobulin
vzig
howev
due
shortag
vzig
year
ago
oral
aciclovir
reconsid
shown
effect
must
rememb
howev
aciclovir
low
bioavail
given
oral
requir
multipl
daili
dose
may
appropri
consid
oral
prodrug
valaciclovir
shown
effect
well
toler
nadal
et
al
work
clarifi
best
prophylact
preemptiv
treatment
regimen
need
fungal
infect
must
consid
specif
circumst
exampl
neutropen
risk
increas
exponenti
durat
neutropenia
steroid
graft
versu
host
diseas
candida
aspergillu
particular
interest
children
undergon
hsct
symptom
rais
suspicion
fungal
infect
persist
fever
unrespons
antibiot
skin
nodul
chest
pain
radiolog
evid
infect
cross
tissu
plane
candida
commonli
associ
cvc
infect
also
caus
dissemin
diseas
aspergillu
infect
insidi
onset
frequent
affect
respiratori
tract
spread
involv
area
spine
intracrani
caviti
investig
diagnosi
remain
difficult
may
requir
antigen
test
pcr
crosssect
imag
biopsi
suspici
lesionsarea
persist
mucocutan
candidiasi
seen
patient
defect
tcell
function
may
present
featur
hiv
infect
primari
immun
defici
dissemin
infect
involv
almost
organ
anatom
site
rapidli
fatal
particular
concern
patient
cvc
especi
receiv
multipl
infus
andor
parenter
nutrit
number
differ
candida
speci
result
dissemin
infect
candia
albican
common
c
parapsilosi
c
glabrata
c
tropicali
c
krusei
increasingli
common
fig
diagnosi
may
difficult
blood
cultur
alway
posit
howev
identif
made
microscopi
biopsi
specimen
suspici
lesion
often
found
organ
liver
kidney
spleen
brain
best
identifi
crosssect
imag
pcr
techniqu
develop
well
detect
antigen
fungal
cell
wall
mannan
howev
techniqu
yet
wholli
reliabl
number
agent
avail
treatment
includ
amphotericin
b
caspofugin
azol
voriconazol
prolong
treatment
usual
requir
cvc
invas
aspergillu
infect
immunocompromis
usual
involv
lung
sinus
brain
skin
commonli
cross
tissu
plane
less
commonli
caus
endocard
osteomyel
mening
infect
around
eye
orbit
caus
angioinvas
result
thrombosi
occasion
eros
blood
vessel
wall
often
catastroph
hemorrhag
consequ
number
aspergillu
speci
caus
invas
diseas
commonli
due
aspergillu
fumigatu
flavu
terreu
nidulan
niger
also
respons
invas
infect
diagnosi
challeng
crosssect
imag
import
identifi
suspici
lesion
aspergillu
infrequ
identifi
blood
commonli
indic
biopsi
specimen
galactomannan
complex
sugar
molecul
found
cell
wall
aspergillu
speci
may
also
identifi
blood
use
aid
diagnosi
treatment
usual
amphotericin
b
voriconazol
caspofungin
requir
prolong
cours
surgic
excis
fungal
lesion
may
requir
especi
signific
area
necrot
tissu
antifung
agent
penetr
effect
also
import
associ
aspergillu
infect
build
work
hospit
site
one
studi
italian
hematolog
unit
found
three
case
proven
aspergillosi
patient
acut
leukemia
coincid
renov
work
hospit
site
high
level
fumigatu
corridor
pini
et
al
highlight
import
highrisk
patient
eg
hsct
steril
isol
cubicl
maintain
posit
pressur
highli
purifi
air
extra
attent
must
paid
reduc
exposur
immunocompromis
patient
build
work
hospit
site
mani
immunocompromis
children
indwel
cvc
treatment
extern
broviac
hickman
line
intern
portacath
although
benefici
unfortun
provid
site
infect
catheterrel
blood
stream
infect
seriou
case
lifethreaten
clinic
featur
catheterrel
blood
stream
infect
nonspecif
diagnosi
often
made
identif
organ
blood
cultur
along
lack
focal
infect
symptomssign
organ
caus
cvc
infect
often
would
nonvirul
normal
flora
immunocompet
host
exampl
coagulas
neg
staphylococci
enterococci
viridan
streptococci
howev
mycobacteri
cvc
infect
also
occur
hawkin
et
al
candida
cvc
infect
prevent
prioriti
line
insert
strict
asept
techniqu
place
access
fulli
train
staff
use
asept
techniqu
local
polici
follow
access
flush
cvc
histor
cvc
often
remov
infect
identifi
howev
mani
patient
left
difficult
situat
poor
venou
access
need
gener
anaesthet
replac
line
mani
catheterrel
blood
stream
infect
treat
antibiot
without
requir
cvc
remov
clinic
suspicion
catheterrel
blood
stream
infect
antibiot
coagulas
neg
staphylococcu
gram
neg
organ
introduc
organ
identifi
blood
cultur
antibiot
tailor
appropri
antibiot
lock
use
alongsid
system
antibiot
reduc
colon
within
cvc
antibiot
lock
involv
instil
ml
concentr
antibiot
solut
cvc
leav
predetermin
time
remov
antibiot
use
studi
treat
cvc
colon
includ
vancomycin
amikacin
minocyclin
also
limit
evid
use
amphotericin
lock
studi
attempt
look
whether
use
lock
alon
combin
system
antibiot
benefit
result
variabl
stage
must
conclud
lock
use
adjunct
system
treatment
enough
evid
suggest
use
alon
immunocompromis
children
cvc
berrington
gould
attempt
present
cvc
infect
antibioticimpregn
cvc
also
develop
recent
systemat
review
found
signific
reduct
catheterrel
blood
stream
infect
heparinco
antibioticimpregn
cvc
compar
standard
cvc
well
coat
chlorhexidin
silver
sulphadiazin
silverimpregn
howev
concern
develop
antibiot
resist
studi
requir
recommend
made
appropri
cvc
use
gilbert
harden
must
rememb
catheterrel
blood
stream
infect
life
threaten
low
threshold
remov
cvc
sign
clinic
deterior
treatment
blood
cultur
drawn
cvc
repeatedli
posit
despit
ongo
appropri
antibiot
treatment
increas
mortal
associ
delay
cathet
remov
aureu
fungal
infect
remov
must
consid
urgent
organ
isol
benefit
remov
cvc
gramneg
organ
identifi
slightli
difficult
assess
due
scarciti
data
howev
like
immedi
remov
contribut
increas
surviv
infect
riskbenefit
ratio
remov
retain
cvc
care
consid
children
receiv
treatment
malign
febril
neutropenia
signific
caus
morbid
mortal
time
outcom
improv
dramat
still
remain
frequent
reason
hospit
shown
schmipff
et
al
henc
empir
antibiot
becom
standard
part
treatment
children
adult
febril
neutropenia
fever
neutropenia
immunocompromis
child
act
promptli
howev
exactli
defin
appropri
manag
vari
wide
highlight
recent
review
febril
neutropenia
manag
unit
kingdom
children
cancer
studi
group
center
phillip
et
al
wide
variat
definit
fever
persist
temperatur
higher
c
singl
read
c
neutropenia
absolut
neutrophil
count
empir
antibiot
regim
also
vari
greatli
includ
aminoglycosid
plu
second
agent
piperacillin
base
cephalosporin
carbapenem
carbapenem
alon
two
case
cefuroxim
plu
flucloxacillin
ciprofloxacin
plu
ceftazidim
time
antifung
therapi
even
variabl
term
start
durat
empir
treatment
variat
explain
variat
organ
isol
antibiot
sensit
unit
unit
seem
account
differ
practic
therefor
although
local
find
influenc
present
pattern
work
requir
devis
framework
within
local
polici
target
specif
patient
popul
microbiolog
flora
implement
specimen
protocol
shown
fig
infect
immunocompromis
children
offer
varieti
challeng
diagnosi
manag
organ
result
mild
selflimit
ill
immunocompet
host
catastroph
effect
immunocompromis
child
sign
symptom
often
less
specif
find
caus
organ
difficult
import
low
threshold
think
infect
look
neg
test
taken
reassur
clinic
suspicion
may
necessari
look
close
import
develop
good
relationship
local
microbiolog
virolog
laboratori
aid
process
infect
identifi
must
act
upon
quickli
delay
may
disastr
treatment
infect
immunocompromis
child
like
intens
prolong
child
fulli
function
immun
system
also
import
consid
prophylaxi
specif
patient
group
specif
situat
eg
post
hsct
unit
defin
polici
guidelin
follow
patient
summari
deal
immunocompromis
child
whatev
reason
suspicion
infect
think
earli
look
care
treat
